Volume 30, Number 2—February 2024
Dispatch
Using Insurance Claims Data to Estimate Blastomycosis Incidence, Vermont, USA, 2011–2020
Brian F. Borah
, Paul Meddaugh, Veronica Fialkowski, and Natalie Kwit
, Paul Meddaugh, Veronica Fialkowski, and Natalie Kwit
Table
Characteristics of patients with blastomycosis, Vermont, USA, 2011–2020*
| Characteristic | All patients | Hospitalized patients | Deaths |
|---|---|---|---|
| Total |
114 (100) |
34 (30) |
4† |
| Sex | |||
| M | 67 (59) | 20 (59) | 1 (25) |
| F |
47 (41) |
14 (41) |
3 (75) |
| Insurance type | |||
| Commercial | 48 (42) | ≤10† | NA |
| Medicare | 42 (37) | 19 (56) | NA |
| Medicaid |
24 (21) |
≤10† |
NA |
| Age category, y | |||
| 0–19 | ≤10‡ | ≤10† | 0 |
| 20–39 | 21 (18) | ≤10† | 0 |
| 40–59 | 40 (35) | 11 (32) | 2 (50) |
| 60–79 | 43 (38) | 12 (35) | 1 (25) |
| ≥80 |
≤10‡ |
≤10† |
1 (25) |
| Median age, y (range) | 55 (0–89) | 56 (3–89) | 59 (45–90) |
*Values are no. (%) except as indicated. †Deaths were identified from different data source than patients and hospitalizations; death rate cannot be calculated. ‡In accordance with the Green Mountain Care Board data use agreement for the Vermont Health Care Uniform Reporting and Evaluation System, all results with a patient count ≤10 must be suppressed.
Page created: December 21, 2023
Page updated: January 24, 2024
Page reviewed: January 24, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.